Trial for Treatment Refractory Trigeminal Neuralgia

NCT03941834 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

65

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Conditions

Trigeminal Neuralgia

Interventions

DRUG: Rimegepant
DRUG: Placebo

Sponsor

Pfizer